AngioDynamics names Eric Honroth President & CEO effective Nov 2, 2026; Jim Clemmer retires after 10 years
ANGIODYNAMICS INC
Honroth, 55, joins as President, CEO and board member on Nov 2, 2026, succeeding Jim Clemmer, who departs the board that day and stays on as a consultant.
Honroth was Global President, Life Science at Getinge and previously ran Getinge's $1.2B North American business; earlier roles at Abbott Vascular, Becton Dickinson, CareFusion, Boston Scientific.
Severance: 18 months base salary and 18 months health coverage if terminated without cause; a Change in Control triggers 24 months salary, lump-sum target bonus and full equity vesting.
Clemmer consulting fee is $30,000/month to Nov 2, 2027; retention pacts with all named executives except Clemmer accelerate RSUs and pro-rate PSUs. Director Howard Donnelly to retire at term end.
On October 2, 2026, the Board of Directors of the Company (the “ Board ”) appointed Eric Honroth to serve as President and Chief Executive Officer of the Company, effective as of November 2, 2026 (the “ Effective Date ”) and concurrently with Mr. Clemmer’s retirement.
Mr. Clemmer has served as a member of the Board since 2016 and his decision to retire was not the result of any disagreement between Mr. Clemmer and the Company on any matter relating to the Company’s operations, polices or practices.
As previously disclosed, James C. Clemmer has announced his intention to retire from his position as the President and Chief Executive Officer of the Company on the earlier of November 30, 2026 and appointment of a successor Chief Executive Officer.
In addition, Mr. Honroth was appointed as a director on the Company’s Board as of the Effective Date, conditioned upon his commencement of service as President and Chief Executive Officer and concurrently with Mr. Clemmer’s retirement from his position as a member of the Board.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Eric Honroth was appointed as President and Chief Executive Officer at ANGIODYNAMICS INC.
Action
appointed
Role
President and Chief Executive Officer
Exact text from the filing
On October 2, 2026, the Board of Directors of the Company (the “ Board ”) appointed Eric Honroth to serve as President and Chief Executive Officer of the Company, effective as of November 2, 2026 (the “ Effective Date ”) and concurrently with Mr. Clemmer’s retirement.
James C. Clemmer retired as Director at ANGIODYNAMICS INC.
Action
retired
Role
Director
Exact text from the filing
Mr. Clemmer has served as a member of the Board since 2016 and his decision to retire was not the result of any disagreement between Mr. Clemmer and the Company on any matter relating to the Company’s operations, polices or practices.
James C. Clemmer retired as President and Chief Executive Officer at ANGIODYNAMICS INC.
Action
retired
Role
President and Chief Executive Officer
Exact text from the filing
As previously disclosed, James C. Clemmer has announced his intention to retire from his position as the President and Chief Executive Officer of the Company on the earlier of November 30, 2026 and appointment of a successor Chief Executive Officer.
Eric Honroth was appointed as Director at ANGIODYNAMICS INC.
Action
appointed
Role
Director
Exact text from the filing
In addition, Mr. Honroth was appointed as a director on the Company’s Board as of the Effective Date, conditioned upon his commencement of service as President and Chief Executive Officer and concurrently with Mr. Clemmer’s retirement from his position as a member of the Board.
This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.